SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dishman Carbogen Amc - Quaterly Results

11 Nov 2022 Evaluate
The sales moved up 26.47% to Rs. 1065.40 millions for the September 2022 quarter as compared to Rs. 842.40 millions during the year-ago period.The Net Loss for the quarter ended September 2022 is Rs. -172.80 millions as compared to Net Loss of Rs. -21.60 millions of corresponding quarter ended September 2021Operating Profit reported a sharp decline to 220.30 millions from 423.40 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 1065.40 842.40 26.47 2101.50 1471.10 42.85 3027.90 2003.20 51.15
Other Income 208.80 160.10 30.42 258.80 342.90 -24.53 657.10 661.50 -0.67
PBIDT 220.30 423.40 -47.97 295.90 646.60 -54.24 999.00 135.00 640.00
Interest 136.20 84.60 60.99 262.20 162.50 61.35 372.30 341.70 8.96
PBDT 84.10 313.80 -73.20 33.70 459.10 -92.66 567.60 -206.70 -374.60
Depreciation 352.00 352.80 -0.23 698.50 701.60 -0.44 1400.70 1413.50 -0.91
PBT -267.90 -39.00 586.92 -664.80 -242.50 174.14 -833.10 -1620.20 -48.58
TAX -95.10 -17.40 446.55 -243.70 -85.70 184.36 -528.40 641.20 -182.41
Deferred Tax -95.10 -17.40 446.55 -243.70 -85.70 184.36 -221.60 461.50 -148.02
PAT -172.80 -21.60 700.00 -421.10 -156.80 168.56 -304.70 -2261.40 -86.53
Equity 313.60 313.60 0.00 313.60 313.60 0.00 313.60 313.60 0.00
PBIDTM(%) 20.68 50.26 -58.86 14.08 43.95 -67.97 32.99 6.74 389.57

Dishman Carbogen Amc Share Price

168.60 -2.00 (-1.17%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×